Revenue
2014
2015
2016
2017
2018
2019
2020
2021
2022
2023
2024
2025
Ocugen, Inc. (OCGN)
Price$1.03Cached quote
Net income
2014
2015
2016
2017
2018
2019
2020
2021
2022
2023
2024
2025
Free cash flow
2014
2015
2016
2017
2018
2019
2020
2021
2022
2023
2024
2025
Total cash / debt
CashTotal debt
2014
2015
2016
2017
2018
2019
2020
2021
2022
2023
2024
2025
Financial statements
| 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $4.4M | $4.1M | $6.0M | $2.5M | $0 | $43,000 | $0 | $0 | $0 | $0 | $0 | $0 |
| Research & development | $39.8M | $32.1M | $39.6M | $56.2M | $35.1M | $6.4M | $8.1M | $10.3M | $15.6M | $21.6M | $23.2M | $26.0M |
| Operating expenses | $67.3M | $58.8M | $71.6M | $91.6M | $58.0M | $21.3M | $14.2M | $16.1M | $24.9M | $30.3M | $31.8M | $32.7M |
| Operating income | −$62.9M | −$54.8M | −$65.5M | −$89.1M | −$58.0M | −$21.3M | −$14.2M | −$16.1M | −$24.9M | −$30.3M | −$31.8M | −$32.7M |
| Operating margin | −1,425.70% | −1,350.36% | −1,085.67% | −3,580.02% | — | −49,500.00% | — | — | — | — | — | — |
| EBITDA | −$60.5M | −$52.9M | −$64.8M | −$88.6M | −$57.8M | −$21.2M | −$14.1M | −$16.1M | −$23.4M | −$28.6M | −$30.2M | −$31.9M |
| EBITDA margin | −1,371.31% | −1,303.50% | −1,074.07% | −3,560.73% | — | −49,267.44% | — | — | — | — | — | — |
| Net income | −$67.8M | −$54.1M | −$63.1M | −$86.8M | −$58.4M | −$21.8M | −$20.2M | −$18.2M | −$26.4M | −$16.2M | −$32.0M | −$22.8M |
| Net profit margin | −1,537.41% | −1,333.02% | −1,045.03% | −3,488.91% | — | −50,748.84% | — | — | — | — | — | — |
| Basic EPSper basic share | -$0.23 | -$0.20 | -$0.26 | -$0.40 | -$0.30 | -$0.31 | -$1.46 | -$0.23 | -$0.99 | -$0.97 | -$2.42 | -$6.85 |
| Diluted EPSper diluted share | -$0.23 | -$0.20 | -$0.26 | -$0.40 | -$0.30 | -$0.31 | -$1.46 | -$0.79 | -$0.99 | -$2.18 | -$2.42 | -$6.85 |
Owners
Reported shareholders
7.96%of listed shares
BlackRock, Inc.27M shares · Jun 30, 2026
View holders
| Holder | % owned |
|---|---|
BlackRock, Inc. | 7.96%27M shares |
STATE STREET CORP | 6.33%21.47M shares |
VANGUARD CAPITAL MANAGEMENT LLC | 4.24%14.37M shares |
MILLENNIUM MANAGEMENT LLC | 4.11%13.94M shares |
GEODE CAPITAL MANAGEMENT, LLC | 2.62%8.87M shares |
RTW INVESTMENTS, LP | 1.97%6.67M shares |
Musunuri Shankar | ≈1.80%6.1M shares |
UBS Group AG | 1.53%5.18M shares |
Ikarian Capital, LLC | 1.17%3.96M shares |
GMT Capital Corp | 1.03%3.51M shares |
MARSHALL WACE, LLP | 1.01%3.41M shares |
VANGUARD PORTFOLIO MANAGEMENT LLC | 0.98%3.33M shares |
Hennion & Walsh Asset Management, Inc. | 0.83%2.83M shares |
NORTHERN TRUST CORP | 0.81%2.75M shares |
VANGUARD FIDUCIARY TRUST CO | 0.70%2.37M shares |
TWO SIGMA INVESTMENTS, LP | 0.66%2.23M shares |
Qube Research & Technologies Ltd | 0.65%2.2M shares |
BANK OF AMERICA CORP /DE/ | 0.59%1.99M shares |
HRT FINANCIAL LP | 0.52%1.77M shares |
Zhang Junge | ≈0.40%1.36M shares |
Percentages use 339.04M shares of this listed class outstanding on Jun 30, 2026. ≈ compares the latest reported holding with a share total from a different date; it is not a confirmed current stake.
Gray completes the 100% scale. Reported positions may overlap; holders have different reporting dates.
Source: SEC Form 13F ↗Updated Sep 29, 2026 · Quarterly data
Insider buys & sells
| Transaction | Insider | Type | Shares | Price | Value | Owned after |
|---|---|---|---|---|---|---|
| Jun 15, 2026Form 4 | Johnson-Greene Treerita EssalimaChief Financial Officer | BuyCommon Stock | 21.0K | $1.23 | $25.8K | 521.0K |
| Nov 26, 2024Form 4 | Fernandes PrabhavathiDirector | BuyCommon Stock | 10.0K | $0.91 | $9.1K | 10.0K |
| Nov 22, 2024Form 4 | Castillo KirstenDirector | BuyCommon Stock | 25.0K | $0.91 | $22.8K | 75.0K |
Community posts
Ocugen receives provisional Bahamas clearance for OCU400 access pathway
Ocugen ($OCGN) received provisional approval and priority designation from the Bahamas’ Longevity and Regenerative Therapies Board for OCU400, its experimental gene therapy for retinitis pigmentosa. The company intends to supply the treatme ...
